904 related articles for article (PubMed ID: 23525574)
21. Vedolizumab as induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Feagan BG; Rutgeerts P; Hanauer S; Colombel JF; Sands BE; Lukas M; Fedorak RN; Lee S; Bressler B; Fox I; Rosario M; Sankoh S; Xu J; Stephens K; Milch C; Parikh A;
N Engl J Med; 2013 Aug; 369(8):711-21. PubMed ID: 23964933
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease.
Watanabe M; Hibi T; Mostafa NM; Chao J; Arora V; Camez A; Petersson J; Thakkar R
J Crohns Colitis; 2014 Nov; 8(11):1407-16. PubMed ID: 24874893
[TBL] [Abstract][Full Text] [Related]
23. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
[TBL] [Abstract][Full Text] [Related]
24. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial.
Fukuda Y; Takazoe M; Sugita A; Kosaka T; Kinjo F; Otani Y; Fujii H; Koganei K; Makiyama K; Nakamura T; Suda T; Yamamoto S; Ashida T; Majima A; Morita N; Murakami K; Oshitani N; Takahama K; Tochihara M; Tsujikawa T; Watanabe M
Am J Gastroenterol; 2008 Jul; 103(7):1721-9. PubMed ID: 18616656
[TBL] [Abstract][Full Text] [Related]
25. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
Sandborn WJ; Colombel JF; Panés J; Castillo M; Robinson AM; Zhou Q; Yang M; Thakkar R
J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
[TBL] [Abstract][Full Text] [Related]
26. Similar response to adalimumab in patients with active Crohn's disease either naive to biologic agents or with prior loss of response or intolerance to infliximab.
Triantafillidis JK; Mantzaris G; Karagiannis J; Papavasilliou E; Papatheodoridis G; Fouskas J; Malgarinos G; Gikas A; Papamichael K; Mathou N; Symboulakis E; Karamanolis D
Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):85-90. PubMed ID: 20509281
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease.
Panaccione R; Colombel JF; Sandborn WJ; Rutgeerts P; D'Haens GR; Robinson AM; Chao J; Mulani PM; Pollack PF
Aliment Pharmacol Ther; 2010 Jun; 31(12):1296-309. PubMed ID: 20298496
[TBL] [Abstract][Full Text] [Related]
28. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
[TBL] [Abstract][Full Text] [Related]
29. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
30. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
Dotan I; Rachmilewitz D; Schreiber S; Eliakim R; van der Woude CJ; Kornbluth A; Buchman AL; Bar-Meir S; Bokemeyer B; Goldin E; Maaser C; Mahadevan U; Seidler U; Hoffman JC; Homoky D; Plasse T; Powers B; Rutgeerts P; Hommes D;
Gut; 2010 Jun; 59(6):760-6. PubMed ID: 20551461
[TBL] [Abstract][Full Text] [Related]
31. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience.
Fortea-Ormaechea JI; González-Lama Y; Casis B; Chaparro M; López Serrano P; Van Domselaar M; Bermejo F; Pajares R; Ponferrada A; Vera MI; Martínez Montiel P; Gisbert JP; Pérez-Calle JL; López San Román A; Abreu L; Menchén LA; Marín-Jiménez I
Gastroenterol Hepatol; 2011; 34(7):443-8. PubMed ID: 21724297
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy.
Castaño-Milla C; Chaparro M; Saro C; Barreiro-de Acosta M; García-Albert AM; Bujanda L; Martín-Arranz MD; Carpio D; Muñoz F; Manceñido N; García-Planella E; Piqueras M; Calvet X; Cabriada JL; Botella B; Bermejo F; Gisbert JP
J Clin Gastroenterol; 2015 Jan; 49(1):34-40. PubMed ID: 25485513
[TBL] [Abstract][Full Text] [Related]
33. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease.
Ordás I; Rimola J; Rodríguez S; Paredes JM; Martínez-Pérez MJ; Blanc E; Arévalo JA; Aduna M; Andreu M; Radosevic A; Ramírez-Morros AM; Pinó S; Gallego M; Jauregui-Amezaga A; Ricart E; Panés J
Gastroenterology; 2014 Feb; 146(2):374-82.e1. PubMed ID: 24177375
[TBL] [Abstract][Full Text] [Related]
34. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; van Assche G; Reinisch W; Colombel JF; D'Haens G; Wolf DC; Kron M; Tighe MB; Lazar A; Thakkar RB
Gastroenterology; 2012 Feb; 142(2):257-65.e1-3. PubMed ID: 22062358
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
36. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study.
Peyrin-Biroulet L; Laclotte C; Bigard MA
Aliment Pharmacol Ther; 2007 Mar; 25(6):675-80. PubMed ID: 17311600
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
Kamm MA; Hanauer SB; Panaccione R; Colombel JF; Sandborn WJ; Pollack PF; Zhou Q; Robinson AM
Aliment Pharmacol Ther; 2011 Aug; 34(3):306-17. PubMed ID: 21645018
[TBL] [Abstract][Full Text] [Related]
38. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
[TBL] [Abstract][Full Text] [Related]
39. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
Colombel JF; Panaccione R; Bossuyt P; Lukas M; Baert F; Vaňásek T; Danalioglu A; Novacek G; Armuzzi A; Hébuterne X; Travis S; Danese S; Reinisch W; Sandborn WJ; Rutgeerts P; Hommes D; Schreiber S; Neimark E; Huang B; Zhou Q; Mendez P; Petersson J; Wallace K; Robinson AM; Thakkar RB; D'Haens G
Lancet; 2017 Dec; 390(10114):2779-2789. PubMed ID: 29096949
[TBL] [Abstract][Full Text] [Related]
40. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
Ng SC; Plamondon S; Gupta A; Burling D; Swatton A; Vaizey CJ; Kamm MA
Am J Gastroenterol; 2009 Dec; 104(12):2973-86. PubMed ID: 19755971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
